Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04020185 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy Study of IMSA101 in Refractory Malignancies
A Phase 1 study, sponsored by ImmuneSensor Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT04020185 is a Phase 1 study that has completed, run by ImmuneSensor Therapeutics. The registered enrollment target is 40 participants.
The verdict
NCT04020185, a Phase 1 study, has completed, sponsored by ImmuneSensor Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II)
Interventions
- DRUG IMSA101
- DRUG Immune checkpoint inhibitor (ICI)
- DRUG Immuno-oncology (IO) therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-09-23 |
| Est. Completion | 2023-09-15 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04020185
The ClinicalTrials.gov registry entry for NCT04020185 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is ImmuneSensor Therapeutics, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which IMSA101 is the first listed.
NCT04020185 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04020185 about?
NCT04020185 is a clinical study titled "Safety and Efficacy Study of IMSA101 in Refractory Malignancies". Open-label, dose escalation (Phase I) and dose expansion (Phase IIA) study of patients receiving intra-tumoral IMSA101 alone or in combination with an immune checkpoint inhibitor (ICI) (Phase I and II)
What is the current status of trial NCT04020185?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-09-23. Estimated completion is 2023-09-15.
What interventions are being tested in trial NCT04020185?
The interventions under investigation include: IMSA101 (DRUG), Immune checkpoint inhibitor (ICI) (DRUG), Immuno-oncology (IO) therapy (DRUG).
Who is sponsoring clinical trial NCT04020185?
This trial is sponsored by ImmuneSensor Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.